The agonist PPAR-γ Pioglitazone has also been shown to increase the functional expression of the glutamate transporter EAAT2 in glioma cells, preventing excitotoxic damage and glutamate-mediated seizures related to glioma [79]. This evidence concerns the gene PPARG and central nervous system cancer.